Investors

Webcast
Ocular Therapeutix at the Piper Sandler 33rd Annual Healthcare Conference
Monday, November 22, 2021 10:00 AM EST
Webcast
Ocular Therapeutix at the Jefferies London Healthcare Conference
Thursday, November 18, 2021 3:00 AM EST
Webcast
Q3 2021 Ocular Therapeutix, Inc. Earnings Conference Call
Monday, November 08, 2021 4:30 PM EST

Corporate Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has received a target action date under the Prescription Drug User Fee Act, commonly known as PDUFA, of October 18, 2021, for a supplemental new drug application for DEXTENZA to include an additional indication for the treatment of ocular itching associated with allergic conjunctivitis...

(Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.